Home › Diffuse Intrinsic Pontine Glioma › Pennsylvania
Diffuse Intrinsic Pontine Glioma clinical trials in Pennsylvania
12 studies for Diffuse Intrinsic Pontine Glioma are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Children's Hospital of Philidelphia, Philidelphia
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated Sep 21, 2026 · NCT06838676CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
RecruitingPhase 1/2
12 Months – 21 Years · All sexes · Updated Sep 11, 2026 · NCT04870944Targeted Pediatric High-Grade Glioma Therapy
- Children's Hospital of Philadelphia, Philadelphia
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
RecruitingPhase 1/2
Up to age 26 · All sexes · Updated Sep 3, 2026 · NCT06465199Study of Olutasidenib and Temozolomide in HGG
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
Ages 3 to 39 · All sexes · Updated Aug 24, 2026 · NCT05096481Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
Ages 1 to 26 · All sexes · Updated Aug 4, 2026 · NCT07680439Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 1/2
Ages 4 to 39 · All sexes · Updated Jul 20, 2026 · NCT05278208Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Children's Hospital of Philadelphia, Philadelphia
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899Combination Therapy for the Treatment of Diffuse Midline Gliomas
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
Ages 2 to 39 · All sexes · Updated Jun 26, 2026 · NCT05009992Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Children's Hospital of Philadelphia, Philadelphia
RecruitingEarly phase 1
Up to age 21 · All sexes · Updated Mar 18, 2026 · NCT04655404From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.